Tempus AI is pushing deeper into drug development partnerships with a new strategic collaboration with Daiichi Sankyo, one centered on a problem that has become increasingly important in oncology: not just building better therapies, but identifying more precisely which patients are most likely to benefit from them. The agreement focuses on accelerating the clinical development and differentiation of an antibody-drug conjugate program by combining Daiichi Sankyo’s clinical trial and preclinical research data with Tempus’ real-world oncology data and AI models.